Elevated Serum Levels of Macrophage Migration Inhibitory Factor (MIF) in Patients with Behcet's Disease.
- Author:
Sung Dong KIM
1
;
Sang Hyon KIM
;
Hae Rim KIM
;
Mi Kyung PARK
;
Chong Hyeon YOON
;
Wan Uk KIM
;
Sang Heon LEE
;
Sung Hwan PARK
;
Chul Soo CHO
;
Ho Youn KIM
Author Information
1. Department of Internal Medicine, Division of Rheumatology, Kangnam St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea. rapark@catholic.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Behcet's disease;
Macrophage migration inhibitory factor (MIF)
- MeSH:
Blood Cells;
Concanavalin A;
Enzyme-Linked Immunosorbent Assay;
Humans;
Inflammation;
Macrophages*
- From:The Journal of the Korean Rheumatism Association
2004;11(3):205-211
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Macrophage migration inhibitory factor (MIF) has emerged recently as an important regulator of inflammatory and immune responses. This work was undertaken to evaluate serum levels of MIF and in vitro MIF production by whole blood cells in patients with Behcet's disease and investigate the relationship between serum levels of MIF and clinical manifestations. METHODS: Sixty-five patients with Behcet's disease and forty-eight healthy controls were studied to evaluate serum levels of MIF. Six patients with Behcet's disease and Five healthy controls were studied for evaluating the production of MIF by whole blood cells. Serum and culture supernatant levels of MIF were measured by enzyme-linked immunosorbent assay (ELISA). The production of MIF by whole blood cells was investigated by culturing peripheral blood cells in the absence or presence of Concanavalin A (Con A). RESULTS: Serum levels of MIF were higher in patients with Behcet's disease than in healthy controls. Serum levels of MIF were changed in each patient with Behcet's disease according to clinical disease activity (higher at active state). The MIF production by Con A-stimulated peripheral blood cell culture was higher in patients with Behcet's disease than in healthy controls. CONCLUSION: Circulating levels of MIF are higher in patients with Behcet's disease than in healthy controls and the levels of MIF may be associated with clinical disease activity. MIF may play an important role as a mediator of inflammation in Behcet's disease and provide opportunity for the development of anti-MIF strategy for the treatment of patients with Behcet's disease.
